MPLT: Needham Raises PT
Needham maintains buy rating on MapLight Therapeutics and raises price target to $42
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.
Needham maintains buy rating on MapLight Therapeutics and raises price target to $42
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.